These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 26749142

  • 1. Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.
    Bouchnita A, Eymard N, Moyo TK, Koury MJ, Volpert V.
    Am J Hematol; 2016 Jun; 91(4):371-8. PubMed ID: 26749142
    [Abstract] [Full Text] [Related]

  • 2. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
    Liu L, Yu Z, Cheng H, Mao X, Sui W, Deng S, Wei X, Lv J, Du C, Xu J, Huang W, Xia S, An G, Zhou W, Ma X, Cheng T, Qiu L, Hao M.
    Sci Rep; 2020 Nov 25; 10(1):20508. PubMed ID: 33239656
    [Abstract] [Full Text] [Related]

  • 3. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.
    Sridhar S, Dutta TK, Basu D.
    J Indian Med Assoc; 2011 Dec 25; 109(12):880-2, 887-8. PubMed ID: 23469567
    [Abstract] [Full Text] [Related]

  • 4. Increase of bone marrow cellularity during erythropoietin treatment in myeloma.
    Ludwig H, Chott A, Fritz E, Krainer M.
    Stem Cells; 1995 Aug 25; 13 Suppl 2():77-87. PubMed ID: 8520516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Wang M, Giralt S, Delasalle K, Handy B, Alexanian R.
    Hematology; 2007 Jun 25; 12(3):235-9. PubMed ID: 17558699
    [Abstract] [Full Text] [Related]

  • 9. Erythropoietin treatment of anemia associated with multiple myeloma.
    Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U.
    N Engl J Med; 1990 Jun 14; 322(24):1693-9. PubMed ID: 2342535
    [Abstract] [Full Text] [Related]

  • 10. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
    Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsonis MC, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, Dimopoulos MA, Greek Myeloma Study Group.
    Am J Hematol; 2014 Jan 14; 89(1):34-40. PubMed ID: 23983166
    [Abstract] [Full Text] [Related]

  • 11. Pleural effusion as a manifestation of multiple myeloma.
    Iqbal N, Tariq MU, Shaikh MU, Majid H.
    BMJ Case Rep; 2016 Aug 12; 2016():. PubMed ID: 27520995
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of causes for anemia in patients with multiple myeloma].
    Rokicka-Piotrowicz M, Paszkowska M, Król M, Król M, Kuratowska Z.
    Pol Arch Med Wewn; 2000 Dec 12; 104(6):843-51. PubMed ID: 11424663
    [Abstract] [Full Text] [Related]

  • 13. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K.
    Hematol Oncol; 2004 Dec 12; 22(4):159-68. PubMed ID: 15991268
    [Abstract] [Full Text] [Related]

  • 14. Posttraumatic pneumonia exacerbates bone marrow erythropoietic dysfunction.
    Gillies GS, Munley JA, Kelly LS, Kirkpatrick SL, Pons EE, Kannan KB, Bible LE, Efron PA, Mohr AM.
    J Trauma Acute Care Surg; 2024 Jan 01; 96(1):17-25. PubMed ID: 37853556
    [Abstract] [Full Text] [Related]

  • 15. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Jan 01; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
    Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S, Baccarani M, Cavo M.
    Eur J Haematol; 2004 Aug 01; 73(2):98-103. PubMed ID: 15245508
    [Abstract] [Full Text] [Related]

  • 18. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G.
    J Clin Oncol; 2012 Jul 10; 30(20):2475-82. PubMed ID: 22585692
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B.
    Clin Lymphoma Myeloma; 2006 Nov 10; 7(3):210-6. PubMed ID: 17229337
    [Abstract] [Full Text] [Related]

  • 20. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG.
    Br J Haematol; 2010 Feb 10; 148(4):562-8. PubMed ID: 19919652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.